By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On March 1, 2024, the U.S. Food and Drug Administration approved amivantamab- vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed for the initial
By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center Tucatinib, a HER2-directed tyrosine kinase inhibitor (TKI), has been approved in combination with trastuzumab and capecitabine for previously treated HER2+ metastatic
MoreBy Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center Development of endocrine resistance remains a challenge in the management of HR-positive HER2-negative breast cancer (HR+ HER2- BC). Alterations in PI3K
MoreBy Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center Data from two phase III trials showed that adding immune checkpoint inhibition in the neoadjuvant setting in HR positive breast cancer was
MoreDecember 6th 2023 / 12:15 PM PST By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On November 15, 2023, the U.S. Food and Drug Administration approved Repotrectinib (Augtyro) for adult patients with locally advanced
MoreThe Binaytara Foundation has proudly announced the 2023 Binaytara Career Advancement Awards recipients. The recipients of the 2023 awards attended Binaytara Foundation’s 2023 Annual Summit on Hematologic Cancers, Nashville, TN, and the
MoreBy: BTF Staff October 28, 2023 – Known for its unwavering commitment to improving access to cancer care in resource-poor communities, the Binaytara Foundation hosted its “2023 Global Oncology Summit.” Central
MoreBy: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), significantly improves overall survival (OS) in renal cell carcinoma (RCC) patients at a higher risk of recurrence post- nephrectomy, according
MoreBy: Dr. Anam Kamal Ascension Providence Hospital; Michigan The standard of care for such patients is platinum-based doublet chemotherapy. In May 2021, the FDA granted accelerated approval to Amivantamab for the treatment
MoreBy: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On October 27, the U.S. Food and Drug Administration approved toripalimab-tpzi (Loqtorzi) in combination with chemotherapy for adult patients with metastatic or locally advanced nasopharyngeal carcinoma
MoreBy: Dr. Kanak Parmar On October 24, 2023 the U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (R/R MDS) with a susceptible isocitrate dehydrogenase-1
More